Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …

The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable
(IGHV) gene is a critical biomarker for assessing the prognosis of patients with chronic …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

The concept of precision cell therapy targeting tumor-specific mutations is appealing but
requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of …

Variation in the antibody response has been linked to differential outcomes in disease, and
suboptimal vaccine and therapeutic responsiveness, the determinants of which have not …

Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical
behavior. In 5–10% of patients the disease transforms into a diffuse large-B cell lymphoma …

Splicing factor 3B subunit 1 (SF3B1) is involved in pre-mRNA branch site recognition and is
the target of antitumor-splicing inhibitors. Mutations in SF3B1 are observed in 15% of …

Lymphoid neoplasms represent a heterogeneous group of disease entities and subtypes
with markedly different molecular and clinical features. Beyond genetic alterations, lymphoid …